GoodLifeSci

GoodLifeSci, published by Sidley Austin LLP, focuses on legal developments and regulatory issues affecting the life sciences sector. The blog covers topics such as pharmaceutical and biotech company compliance, drug pricing policies in the U.S. and internationally, securities and disclosure regulations impacting life sciences firms, and corporate governance matters relevant to the industry. It also addresses emerging regulatory frameworks like the European Health Data Space Regulation and provides insights on litigation trends, market challenges, and strategic considerations for life sciences companies navigating complex legal and financial environments.

Latest from GoodLifeSci - Page 3

On August 7, 2025, the U.S. Food and Drug Administration (FDA) announced FDA PreCheck, a new two-phase framework aimed at bolstering the domestic pharmaceutical supply chain by streamlining the regulatory process for U.S.-based drug manufacturing facilities. Notably, the announcement also included…